Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 11:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 1,565 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control regimen Clear all
Completed Phase 3 Interventional

A Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT00570986
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Placebo, ABT-874
Drug · Biological
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
1,465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
93
States / cities
Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 76 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2013 · Synced Oct 29, 2026, 11:43 AM EDT
Completed Phase 4 Interventional Results available

A Within Subjects Comparison of Two Antegrade Flushing Regimens in Children

NCT02435069
View directory record Official record
Conditions
Fecal Incontinence, Neurogenic Bowel
Interventions
Dose Response - NS and USP Glycerin - First Intervention, Effectiveness - NS and USP Glycerin - Second Intervention
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
3 Years to 12 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 29, 2026, 11:43 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Reducing Sedentary Time in Chronic Low Back Pain: Sedentary Intervention Using Motivational Interviewing and Technology

NCT04257539
View directory record Official record
Conditions
Chronic Low-back Pain
Interventions
Intervention to Reduce Sedentary Time
Behavioral
Lead sponsor
Iowa State University
Other
Eligibility
25 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Ames, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Oct 29, 2026, 11:43 AM EDT
Completed Phase 3 Interventional

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Alone

NCT01691846
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
aleglitazar+metformin, placebo+metformin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
22
States / cities
Chino, California • Hawaiian Gardens, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 29, 2026, 11:43 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Study is to Evaluate a Regimen on Gingivitis Using Traditional and Novel Assessment Methods

NCT07211061
View directory record Official record
Conditions
Gingivitis
Interventions
Stannous Fluoride Dentifrice, Sodium Fluoride Dentifrice, electric toothbrush, Cetylpyridinium Chloride (CPC), manual toothbrush
Drug · Device
Lead sponsor
Procter and Gamble
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Oct 29, 2026, 11:43 AM EDT
Terminated Phase 2 Interventional

Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis

NCT05048056
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Placebo, AK120
Drug
Lead sponsor
Akesobio Australia Pty Ltd
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
16
States / cities
Little Rock, Arkansas • Canoga Park, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Oct 29, 2026, 11:43 AM EDT
Recruiting Phase 3 Interventional

D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM

NCT07624513
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Isatuximab, Iberdomide, Bortezomib (B), Dexamethasone, Melphalan, Linvoseltamab, On Body Delivery System (OBDS)
Drug · Device
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2038
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 29, 2026, 11:43 AM EDT
Completed Phase 3 Interventional

Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY)

NCT01479283
View directory record Official record
Conditions
Infection, Bone Neoplasms
Interventions
24-Hour Prophylactic Cefazolin* Antibiotic Regimen, 5-Days Prophylactic Cefazolin* Antibiotic Regimen
Drug
Lead sponsor
McMaster University
Other
Eligibility
12 Years and older
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
34
States / cities
Little Rock, Arkansas • Los Angeles, California • Redwood City, California + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2021 · Synced Oct 29, 2026, 11:43 AM EDT
Completed Not applicable Interventional

Exercise for People with Spinal Cord Injury

NCT04007445
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Formally Directed Group (Exercise Group), Self-Directed Group (Control Group)
Behavioral · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 29, 2026, 11:43 AM EDT
Completed Phase 2 Interventional

Mobile Technology and Online Tools to Track Adherence in Chronic Illness Patients

NCT02864641
View directory record Official record
Conditions
Renal Insufficiency, Chronic
Interventions
Planet K
Behavioral
Lead sponsor
3-C Institute for Social Development
Industry
Eligibility
12 Years to 21 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 12, 2016 · Synced Oct 29, 2026, 11:43 AM EDT
Completed Phase 4 Interventional Results available

Vitamin D Repletion in Primary Hyperparathyroidism

NCT01306656
View directory record Official record
Conditions
Primary Hyperparathyroidism, Vitamin D Deficiency
Interventions
10,000 IU Vitamin D3, Placebo, Vitamin D
Drug · Other · Dietary Supplement
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 29, 2026, 11:43 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

AnteAGE Biosomes With Radiofrequency Microneedling for Facial Skin Rejuvenation

NCT07849556
View directory record Official record
Conditions
Skin Aging, Facial Rhytides, Skin Tone
Interventions
AnteAGE Biosome Treatment Solution, Radiofrequency Microneedling, AnteAGE Homecare Regimen
Other · Device
Lead sponsor
Cellese Inc.
Industry
Eligibility
30 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 29, 2026, 11:43 AM EDT
Completed Phase 3 Interventional Results available

Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors

NCT00572572
View directory record Official record
Conditions
Germ Cell Tumors
Interventions
Aprepitant, Placebo
Drug
Lead sponsor
Hoosier Cancer Research Network
Other
Eligibility
15 Years and older · Male only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
6
States / cities
Indianapolis, Indiana • Muncie, Indiana • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2016 · Synced Oct 29, 2026, 11:43 AM EDT
Completed Not applicable Interventional

Adding Maraviroc to the HAART Regimen of Well Controlled HIV-infected Patients

NCT02934022
View directory record Official record
Conditions
HIV Infection
Interventions
Maraviroc
Drug
Lead sponsor
Southern California Institute for Research and Education
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2016 · Synced Oct 29, 2026, 11:43 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

NCT04588922
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
SLS009, venetoclax, azacitidine
Drug
Lead sponsor
Sellas Life Sciences Group
Industry
Eligibility
12 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
19
States / cities
Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 29, 2026, 11:43 AM EDT
Completed Not applicable Interventional Results available

The Summer Camp Study 2: Blood Glucose Control With a Bi-Hormonal Endocrine Pancreas

NCT02105324
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Bionic Pancreas, Usual Care
Device · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 11 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 20, 2017 · Synced Oct 29, 2026, 11:43 AM EDT
Active, not recruiting Phase 2 Interventional

ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis

NCT07090330
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
ORKA-001 Induction Dose, Placebo, ORKA-001 Maintenance Dose
Drug · Other
Lead sponsor
Oruka Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
17
States / cities
Fountain Valley, California • Los Angeles, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 29, 2026, 11:43 AM EDT
Completed Phase 4 Interventional Results available

Cohort 2 (Abdominoplasty) of: A Multi-surgery Assessment of ZYNRELEF (HTX-011)

NCT06109428
View directory record Official record
Conditions
Postoperative Pain, Abdominoplasty Surgery, Multimodal Analgesia
Interventions
MMA regimen, ZYNRELEF kit components for administration, HTX-011, Bupivacaine Hydrochloride
Drug · Device
Lead sponsor
Heron Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Bellaire, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Oct 29, 2026, 11:43 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

ImmunoBoost: The Lymphatic Osteopathic Manipulative Treatment Protocol Study

NCT06565065
View directory record Official record
Conditions
Healthy
Interventions
Osteopathic Manipulative Treatment (OMT), Sham Light Touch, Exercise Protocol
Procedure · Other
Lead sponsor
Western University of Health Sciences
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Pomona, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 29, 2026, 11:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Alternate Dosing Regimens of BG00012 in Healthy Volunteers

NCT01281111
View directory record Official record
Conditions
Healthy
Interventions
Dimethyl Fumarate (BG00012), Aspirin, BG00012 matching placebo, ASA matching placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Oct 29, 2026, 11:43 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Iduronate-2-sulfatase Enzyme Replacement Therapy in Mucopolysaccharidosis II (MPS II)

NCT00069641
View directory record Official record
Conditions
Mucopolysaccharidosis II
Interventions
iduronate-2-sulfatase enzyme replacement therapy, Placebo
Biological
Lead sponsor
Shire
Industry
Eligibility
5 Years to 25 Years · Male only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
4
States / cities
Oakland, California • St Louis, Missouri • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Oct 29, 2026, 11:43 AM EDT
Completed Phase 2 Interventional

Study to Investigate the Efficacy and Tolerability of AZD1446 in Adult ADHD Patients.

NCT01012375
View directory record Official record
Conditions
Adult ADHD
Interventions
AZD1446, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
6
States / cities
Los Alamitos, California • Fort Myers, Florida • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2011 · Synced Oct 29, 2026, 11:43 AM EDT
Completed Not applicable Interventional

Remote Patient Monitoring and Health Coaching vs. Usual Care for the Treatment of Hypertension

NCT05394766
View directory record Official record
Conditions
Hypertension
Interventions
Omada Hypertension Program
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 29, 2026, 11:43 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT03434041
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Esketamine 56 mg, Esketamine 84 mg, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
6
States / cities
Atlanta, Georgia • Shreveport, Louisiana • Gaithersburg, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 29, 2026, 11:43 AM EDT